Evidence map›Paper›PMID 39250132›Full record

SynthesisJAMA neurology2024

Role of the X Chromosome in Alzheimer Disease Genetics.

Michael E Belloy, Yann Le Guen, Ilaria Stewart, Kennedy Williams, Joachim Herz, Richard Sherva, Rui Zhang, Victoria Merritt, Matthew S Panizzon, Richard L Hauger and 4 more

Abstract readMeta-Analysis
In one paragraph

Synthesis in JAMA neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. APOE*4 risk-modifying genes and drug targets in Alzheimer's disease through cell-type-specific genomic analyses.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Genetic Analysis of the X Chromosome Associates Loci with Progression of Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Michael E BelloyDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.
Yann Le GuenDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.
Ilaria StewartDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.
Kennedy WilliamsDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.
Joachim HerzCenter for Translational Neurodegeneration Research, Department of Molecular Genetics University of Texas Southwestern Medical Center at Dallas, Dallas.
Richard ShervaBiomedical Genetics, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts.
Rui ZhangNational Center for PTSD, Behavioral Sciences Division, VA Boston Healthcare System, Boston, Massachusetts.
Victoria MerrittCenter of Excellence for Stress and Mental Health, VA San Diego Healthcare System, San Diego, California.
Matthew S PanizzonDepartment of Psychiatry, University of California San Diego, La Jolla.
Richard L HaugerCenter of Excellence for Stress and Mental Health, VA San Diego Healthcare System, San Diego, California.
J Michael GazianoMillion Veteran Program (MVP) Coordinating Center, VA Boston Healthcare System, Boston, Massachusetts.
Mark LogueBiomedical Genetics, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts.
Valerio NapolioniSchool of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy.
Michael D GreiciusDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.

Funding

National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8M
Early Cognitive Impairment as a Function of Alzheimer’s Disease Genes and TraumaI01BX004192 · VA · VA BOSTON HEALTH CARE SYSTEM · PI LOGUE, MARK W · 2019 to 2024
–
Early Cognitive Impairment as a function of Alzheimer's Disease and TraumaI01BX005749 · VA · VA BOSTON HEALTH CARE SYSTEM · PI MARK W LOGUE · 2023 to 2026
–
BLRD VA I01 BX004192BLRD VA I01 BX005749NIA NIH HHS U24 AG021886
6 · The paper itself

Abstract

Importance: The X chromosome has remained enigmatic in Alzheimer disease (AD), yet it makes up 5% of the genome and carries a high proportion of genes expressed in the brain, making it particularly appealing as a potential source of unexplored genetic variation in AD. Objectives: To perform the first large-scale X chromosome-wide association study (XWAS) of AD. Design, Setting, and Participants: This was a meta-analysis of genetic association studies in case-control, family-based, population-based, and longitudinal AD-related cohorts from the US Alzheimer's Disease Genetics Consortium, the Alzheimer's Disease Sequencing Project, the UK Biobank, the Finnish health registry, and the US Million Veterans Program. Risk of AD was evaluated through case-control logistic regression analyses. Data were analyzed between January 2023 and March 2024. Genetic data available from high-density single-nucleotide variant microarrays and whole-genome sequencing and summary statistics for multitissue expression and protein quantitative trait loci available from published studies were included, enabling follow-up genetic colocalization analyses. A total of 1 629 863 eligible participants were selected from referred and volunteer samples, 477 596 of whom were excluded for analysis exclusion criteria. The number of participants who declined to participate in original studies was not available. Main Outcome and Measures: Risk of AD, reported as odds ratios (ORs) with 95% CIs. Associations were considered at X chromosome-wide (P < 1 × 10-5) and genome-wide (P < 5 × 10-8) significance. Primary analyses are nonstratified, while secondary analyses evaluate sex-stratified effects. Results: Analyses included 1 152 284 participants of non-Hispanic White, European ancestry (664 403 [57.7%] female and 487 881 [42.3%] male), including 138 558 individuals with AD. Six independent genetic loci passed X chromosome-wide significance, with 4 showing support for links between the genetic signal for AD and expression of nearby genes in brain and nonbrain tissues. One of these 4 loci passed conservative genome-wide significance, with its lead variant centered on an intron of SLC9A7 (OR, 1.03; 95% CI, 1.02-1.04) and colocalization analyses prioritizing both the SLC9A7 and nearby CHST7 genes. Of these 6 loci, 4 displayed evidence for escape from X chromosome inactivation with regard to AD risk. Conclusion and Relevance: This large-scale XWAS of AD identified the novel SLC9A7 locus. SLC9A7 regulates pH homeostasis in Golgi secretory compartments and is anticipated to have downstream effects on amyloid β accumulation. Overall, this study advances our knowledge of AD genetics and may provide novel biological drug targets. The results further provide initial insights into elucidating the role of the X chromosome in sex-based differences in AD.

Indexed as

Alzheimer DiseaseChromosomes, Human, XCase-Control StudiesFemaleGenetic Association StudiesGenetic Predisposition to DiseaseHumansMalePolymorphism, Single Nucleotide

Identifiers

PMID39250132
PMCPMC11385320

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.